A survey of 400 biologics-prescribing physicians found they want labels that clearly indicate if a drug is a biosimilar. This was just one data point they said would shore up their confidence in biosimilars.

The survey was conducted by the industry- and professional-supported Alliance for Safe Biologic Medicines. The ASBM said the survey also showed that the longer a doctor had been practicing, the more likely he or she were to want this information on a biosimilar’s label.

Among the physicians’ label requests:

  • State indications for which the branded biologic is approved and the ones for which the biosimilar is not

  • Share data that shows the similarity between the biosimilar and the branded biologic